PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study.
Humans
Female
Breast Neoplasms
/ mortality
Ethiopia
/ epidemiology
Middle Aged
Adult
Prospective Studies
Aged
Receptors, Estrogen
/ metabolism
Receptor, ErbB-2
/ metabolism
Rural Population
Receptors, Progesterone
/ metabolism
Prognosis
Biomarkers, Tumor
/ metabolism
Gene Expression Profiling
Immunohistochemistry
Chemotherapy, Adjuvant
/ methods
Africa
Breast Cancer
Ethiopia
Intrinsic subtypes
PAM50
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
received:
16
05
2024
accepted:
27
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
10
9
2024
Statut:
epublish
Résumé
Survival rates of breast cancer (BC) patients are particularly low in rural regions in sub-Saharan Africa (SSA) which is due to limited access to therapy. In recent years, gene expression profiling (GEP) of BC showed a strong prognostic value in patients with local tumour surgery and (neo)adjuvant treatment. The aim of this study was to evaluate the impact of intrinsic subtypes on survival of patients in rural Ethiopia without any (neo)adjuvant therapy. In total, 113 female patients from Aira Hospital with histologically proven BC and treated only with surgery were included in this study. All samples were analysed by immunohistochemistry (IHC) for estrogen receptor, progesterone receptor, HER2 and Ki67, as well as RNA-expression analysis for PAM50 subtyping. A positive hormone receptor status was found in 69.0% of the tumours and intrinsic subtyping demonstrated Luminal B to be the most common subtype (34.5%). Follow-up data was available for 79 of 113 patients. Two-year overall survival (OS) was 57.3% and a considerably worse OS was observed in patients with Basal-like BC compared to Luminal A BC. Moreover, advanced tumours showed an increased risk of mortality. The OS was very low in the patient cohort that received no (neo)adjuvant treatment. Immunohistochemistry and GEP confirmed endocrine-sensitive tumours in more than half of the patients, with a large proportion of Luminal B, HER2-enriched and Basal-like tumours so that adjuvant chemotherapy should be recommended.
Identifiants
pubmed: 39256703
doi: 10.1186/s12885-024-12867-6
pii: 10.1186/s12885-024-12867-6
doi:
Substances chimiques
Receptors, Estrogen
0
Receptor, ErbB-2
EC 2.7.10.1
Receptors, Progesterone
0
Biomarkers, Tumor
0
ERBB2 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1127Informations de copyright
© 2024. The Author(s).
Références
International Agency for Research on Cancer, World Health Organization. The Global Cancer Observatory. Population fact sheet: Africa. Source: Globocan 2020. Accessed 21 Aug 2023.
Joko-Fru WY, Miranda-Filho A, Soerjomataram I, et al. Breast cancer survival in sub-saharan Africa by age, stage at diagnosis and human development index: a population-based registry study. Int J Cancer. 2020;146(5):1208–18. https://doi.org/10.1002/ijc.32406 .
doi: 10.1002/ijc.32406
pubmed: 31087650
Gakwaya A, Kigula-Mugambe JB, Kavuma A, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008;99(1):63–7. https://doi.org/10.1038/sj.bjc.6604435 .
doi: 10.1038/sj.bjc.6604435
pubmed: 18577991
pmcid: 2453032
Kantelhardt EJ, Zerche P, Mathewos A, et al. Breast cancer survival in Ethiopia: a cohort study of 1,070 women. Int J Cancer. 2014;135(3):702–9. https://doi.org/10.1002/ijc.28691 .
doi: 10.1002/ijc.28691
pubmed: 24375396
Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11(2):165–73. https://doi.org/10.1016/S1470-2045(09)70335-3 .
doi: 10.1016/S1470-2045(09)70335-3
pubmed: 20005175
Grosse Frie K, Samoura H, Diop S, et al. Why do women with breast Cancer get diagnosed and treated late in Sub-saharan Africa? Perspectives from women and patients in Bamako, Mali. Breast care (Basel. Switzerland). 2018;13(1):39–43. https://doi.org/10.1159/000481087 .
doi: 10.1159/000481087
Ziegenhorn H-V, Frie KG, Ekanem I-O, et al. Breast cancer pathology services in sub-saharan Africa: a survey within population-based cancer registries. BMC Health Serv Res. 2020;20(1):912. https://doi.org/10.1186/s12913-020-05752-y .
doi: 10.1186/s12913-020-05752-y
pubmed: 33008380
pmcid: 7531092
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. https://doi.org/10.1038/35021093 .
doi: 10.1038/35021093
pubmed: 10963602
Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncology: Official J Am Soc Clin Oncol. 2009;27(8):1160–7. https://doi.org/10.1200/JCO.2008.18.1370 .
doi: 10.1200/JCO.2008.18.1370
Caan BJ, Sweeney C, Habel LA, et al. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. Cosponsored Am Soc Prev Oncol. 2014;23(5):725–34. https://doi.org/10.1158/1055-9965.EPI-13-1017 .
doi: 10.1158/1055-9965.EPI-13-1017
Ades F, Zardavas D, Bozovic-Spasojevic I, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncology: Official J Am Soc Clin Oncol. 2014;32(25):2794–803. https://doi.org/10.1200/JCO.2013.54.1870 .
doi: 10.1200/JCO.2013.54.1870
Eng A, McCormack V, Dos-Santos-Silva I. Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med. 2014;11(9):e1001720. https://doi.org/10.1371/journal.pmed.1001720 .
doi: 10.1371/journal.pmed.1001720
pubmed: 25202974
pmcid: 4159229
Bastien RRL, Rodríguez-Lescure Á, Ebbert MTW, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genom. 2012;5:44. https://doi.org/10.1186/1755-8794-5-44 .
doi: 10.1186/1755-8794-5-44
Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin cancer Research: Official J Am Association Cancer Res. 2012;18(16):4465–72. https://doi.org/10.1158/1078-0432.CCR-12-0286 .
doi: 10.1158/1078-0432.CCR-12-0286
Kim HK, Park KH, Kim Y, et al. Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast Cancer patients: potential implication of genomic alterations of discordance. Cancer Res Treat. 2019;51(2):737–47. https://doi.org/10.4143/crt.2018.342 .
doi: 10.4143/crt.2018.342
pubmed: 30189722
Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin cancer Research: Official J Am Association Cancer Res. 2010;16(21):5222–32. https://doi.org/10.1158/1078-0432.CCR-10-1282 .
doi: 10.1158/1078-0432.CCR-10-1282
Dix-Peek T, Phakathi BP, van den Berg EJ, et al. Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer. Breast Cancer Res Treat. 2023;199(1):1–12. https://doi.org/10.1007/s10549-023-06886-3 .
doi: 10.1007/s10549-023-06886-3
pubmed: 36867282
pmcid: 10147771
Okubazgi G, Berhane B, Nigussie M, et al. Status of Histopathology services in Ethiopia. Am J Clin Pathol. 2020;153(1):3–4. https://doi.org/10.1093/ajcp/aqz144 .
doi: 10.1093/ajcp/aqz144
pubmed: 31586440
Eber-Schulz P, Tariku W, Reibold C, et al. Survival of breast cancer patients in rural Ethiopia. Breast Cancer Res Treat. 2018;170(1):111–8. https://doi.org/10.1007/s10549-018-4724-z .
doi: 10.1007/s10549-018-4724-z
pubmed: 29479644
McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387–91. https://doi.org/10.1038/sj.bjc.6602678 .
doi: 10.1038/sj.bjc.6602678
pubmed: 16106245
pmcid: 2361579
Lokuhetty D, White VA, Watanabe R, et al. editors. (2019) Breast tumours, 5th ed. World Health Organization Classification of tumours, vol 2. International Agency for Research on Cancer, Lyon.
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP Guideline Update. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(12):1346–66. https://doi.org/10.1200/JCO.19.02309 .
doi: 10.1200/JCO.19.02309
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36(20):2105–22. https://doi.org/10.1200/JCO.2018.77.8738 .
doi: 10.1200/JCO.2018.77.8738
Petrelli F, Viale G, Cabiddu M, et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477–91. https://doi.org/10.1007/s10549-015-3559-0 .
doi: 10.1007/s10549-015-3559-0
pubmed: 26341751
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast Cancer 2011. Annals Oncology: Official J Eur Soc Med Oncol. 2011;22(8):1736–47. https://doi.org/10.1093/annonc/mdr304 .
doi: 10.1093/annonc/mdr304
Tolaney SM, Garrett-Mayer E, White J, et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast Cancer clinical trials: STEEP Version 2.0. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39(24):2720–31. https://doi.org/10.1200/JCO.20.03613 .
doi: 10.1200/JCO.20.03613
Hamdi Y, Abdeljaoued-Tej I, Zatchi AA, et al. Cancer in Africa: the Untold Story. Front Oncol. 2021;11:650117.
doi: 10.3389/fonc.2021.650117
pubmed: 33937056
pmcid: 8082106
Weiner CM, Mathewos A, Addissie A, et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women. Breast (Edinburgh Scotland). 2018;42:23–30. https://doi.org/10.1016/j.breast.2018.08.095 .
doi: 10.1016/j.breast.2018.08.095
pubmed: 30149234
McCormack V, McKenzie F, Foerster M, et al. Breast cancer survival and survival gap apportionment in sub-saharan Africa (ABC-DO): a prospective cohort study. Lancet Global Health. 2020;8(9):e1203–12. https://doi.org/10.1016/S2214-109X(20)30261-8 .
doi: 10.1016/S2214-109X(20)30261-8
pubmed: 32827482
Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J cancer Res. 2015;5(10):2929–43.
pubmed: 26693050
pmcid: 4656721
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x .
doi: 10.1111/j.1365-2559.1991.tb00229.x
pubmed: 1757079
Oliveira LC, Megid TBC, Rosa DD, et al. Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. JCO. 2022;40(16suppl):e18822–18822. https://doi.org/10.1200/JCO.2022.40.16_suppl.e18822 .
doi: 10.1200/JCO.2022.40.16_suppl.e18822
Hercules SM, Alnajar M, Chen C, et al. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ open. 2022;12(5):e055735. https://doi.org/10.1136/bmjopen-2021-055735 .
doi: 10.1136/bmjopen-2021-055735
pubmed: 35623750
pmcid: 9150263
Kantelhardt EJ, Mathewos A, Aynalem A, et al. The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC Cancer. 2014;14:895. https://doi.org/10.1186/1471-2407-14-895 .
doi: 10.1186/1471-2407-14-895
pubmed: 25433805
pmcid: 4258259
Hadgu E, Seifu D, Tigneh W, et al. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health. 2018;18(1):40. https://doi.org/10.1186/s12905-018-0531-2 .
doi: 10.1186/s12905-018-0531-2
pubmed: 29444670
pmcid: 5813361
Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). https://doi.org/10.1093/jnci/dju055 .
Brandão M, Guisseve A, Bata G, et al. Breast cancer subtypes: implications for the treatment and survival of patients in Africa-a prospective cohort study from Mozambique. ESMO Open. 2020;5(5):e000829. https://doi.org/10.1136/esmoopen-2020-000829 .
doi: 10.1136/esmoopen-2020-000829
pubmed: 33020218
pmcid: 7537337
Ikeri NZ, Oguntunde OA, Igbokwe U, et al. Breast Cancer in a Lagos Facility: implications for the Institution of a Cancer Screening Programme. Pathobiol J ImmunoPathol Mol Cell Biol. 2018;85(4):254–60. https://doi.org/10.1159/000489933 .
doi: 10.1159/000489933
Bauer M, Vetter M, Stückrath K, et al. Regional Variation in the Tumor Microenvironment, Immune escape and prognostic factors in breast Cancer in Sub-saharan Africa. Cancer Immunol Res. 2023;11(6):720–31. https://doi.org/10.1158/2326-6066.CIR-22-0795 .
doi: 10.1158/2326-6066.CIR-22-0795
pubmed: 37058582
pmcid: 10552870
Ansari-Pour N, Zheng Y, Yoshimatsu TF, et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021;12(1):6946. https://doi.org/10.1038/s41467-021-27079-w .
doi: 10.1038/s41467-021-27079-w
pubmed: 34836952
pmcid: 8626467
Kensler KH, Sankar VN, Wang J, et al. PAM50 molecular intrinsic subtypes in the nurses’ health study cohorts. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. Cosponsored Am Soc Prev Oncol. 2019;28(4):798–806. https://doi.org/10.1158/1055-9965.EPI-18-0863 .
doi: 10.1158/1055-9965.EPI-18-0863
Sweeney C, Bernard PS, Factor RE et al. (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 23(5):714–724. https://doi.org/10.1158/1055-9965.EPI-13-1023
Desalegn Z, Yohannes M, Porsch M, et al. Intrinsic subtypes in Ethiopian breast cancer patient. Breast Cancer Res Treat. 2022;196(3):495–504. https://doi.org/10.1007/s10549-022-06769-z .
doi: 10.1007/s10549-022-06769-z
pubmed: 36282363
pmcid: 9633534
Phakathi B, Dix-Peek T, van den Berg E, et al. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study. Breast Cancer Res Treat. 2023;200(3):337–46. https://doi.org/10.1007/s10549-023-06969-1 .
doi: 10.1007/s10549-023-06969-1
pubmed: 37266756
pmcid: 10300149
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast Cancer 2013. Annals Oncology: Official J Eur Soc Med Oncol. 2013;24(9):2206–23. https://doi.org/10.1093/annonc/mdt303 .
doi: 10.1093/annonc/mdt303
Bryan S, Masoud H, Weir HK, et al. Cancer in Canada: stage at diagnosis. Health Rep. 2018;29(12):21–5.
pubmed: 30566206
Johnson HM, Irish W, Vohra NA, et al. Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator. Breast Cancer Res Treat. 2021;187(3):805–14. https://doi.org/10.1007/s10549-021-06113-x .
doi: 10.1007/s10549-021-06113-x
pubmed: 33609208
Reibold CF, Tariku W, Eber-Schulz P, et al. Adherence to newly implemented tamoxifen therapy for breast Cancer patients in Rural Western Ethiopia. Breast care (Basel Switzerland). 2021;16(5):484–90. https://doi.org/10.1159/000512840 .
doi: 10.1159/000512840
pubmed: 34720808
Getachew S, Addissie A, Seife E, et al. Breast nurse intervention to improve adherence to endocrine therapy among breast Cancer patients in South Ethiopia. Oncologist. 2022;27(8):e650–60. https://doi.org/10.1093/oncolo/oyac081 .
doi: 10.1093/oncolo/oyac081
pubmed: 35524760
pmcid: 9355816
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181–7. https://doi.org/10.1002/1097-0142(19890101)63:1%3C181:AID-CNCR2820630129%3E3.0.CO;2-H .
doi: 10.1002/1097-0142(19890101)63:1<181:AID-CNCR2820630129>3.0.CO;2-H
pubmed: 2910416
Liu MC, Pitcher BN, Mardis ER, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer. 2016;2:15023. https://doi.org/10.1038/npjbcancer.2015.23 .
doi: 10.1038/npjbcancer.2015.23
pubmed: 28691057
pmcid: 5501351
Cubasch H, Ruff P, Joffe M, et al. South African breast Cancer and HIV outcomes Study: methods and Baseline Assessment. J Global Oncol. 2017;3(2):114–24. https://doi.org/10.1200/JGO.2015.002675 .
doi: 10.1200/JGO.2015.002675
Phakathi B, Nietz S, Cubasch H, et al. Survival of South African women with breast cancer receiving anti-retroviral therapy for HIV. Breast (Edinburgh Scotland). 2021;59:27–36. https://doi.org/10.1016/j.breast.2021.05.014 .
doi: 10.1016/j.breast.2021.05.014
pubmed: 34126376